Understanding how genetic differences affect heart responses to cancer drugs
Single-Cell RNA Sequencing of Cardiac Organoids to Determine the Genetic Basis for Cell-Specific Responses to Anticancer Drugs
This study is looking at how our genes affect how our hearts react to certain cancer treatments, which can sometimes harm the heart, and it's for cancer patients who want to understand how their unique genetics might change their treatment experience.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11062344 on NIH RePORTER |
What this research studies
This research investigates how genetic variations influence the heart's response to anticancer drugs, which can cause cardiovascular toxicity in patients. By using advanced single-cell RNA sequencing techniques, the study aims to analyze multiple cardiac cell types from a diverse group of individuals. This approach will help identify specific genetic factors that contribute to varying responses to drugs like doxorubicin and 5-fluorouracil. Ultimately, the goal is to improve treatment protocols for cancer patients by understanding their unique genetic backgrounds.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are undergoing treatment with drugs known to cause cardiovascular toxicity.
Not a fit: Patients who are not currently receiving anticancer treatments or those without cardiovascular concerns may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to personalized cancer treatment strategies that minimize cardiovascular side effects for patients.
How similar studies have performed: Previous research has shown that understanding genetic factors can significantly improve treatment outcomes in various medical fields, suggesting a promising avenue for this approach.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Mcintire, Erik — University of Chicago
- Study coordinator: Mcintire, Erik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.